Top Posts Tagged with #embryoscreening

Popular Recent

Get in-depth analysis of the in vitro fertilization market report 2026! In this comprehensive report, we provide insights into the key trends, market dynamics, and growth opportunities shaping the in vitro fertilization industry. Whether you're a industry professional, an investor, or looking to know about the market trends, this report is your go-to resource.

Key Highlights:

Global Market Overview: Get insights into the historical and forecast data of the in vitro fertilization market Market Trends and Drivers: Explore the latest trends and factors influencing market sector, fund size, and funding type. Industry Segment Analysis: Understand Industry Segmentation the market based on product, procedure type, cycle type, and end user. Regional Analysis: Get regional Insights and market dynamics impacting different geographical areas. Competitive Landscape: Read about comprehensive overview of key players, their strategies, and market positioning. Report Edition: 2026-2034

Who Should Watch?

Industry Professionals Investors and Stakeholders Researchers and Analysts Food and Beverage Enthusiasts Business Owners and Entrepreneurs

Report Links: https://www.imarcgroup.com/In-Vitro-Fertilization-Market

Youtube Link: https://youtu.be/Xeh40JYtzis

Contact Us: IMARC Group 134 N 4th St. Brooklyn, NY 11249, USA Email: [email protected] Tel No: (D) +91 120 433 0800 USA - +1 201971-6302

#IVFTech #FertilityInnovation #AssistedReproduction #EmbryoScreening #FamilyPlanningFuture #Youtube

•18+ Adults Only

Watch Anya Live on Cam

Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.

✓ Live Streaming✓ Interactive Chat✓ Private Shows✓ HD Quality

Anya is LIVE right now

FREE

Free to watch • No registration required • HD streaming

Preimplantation Genetic Testing for Aneuploidy (PGT-A) has become an increasingly common tool in assisted reproductive technology (ART), especially for couples undergoing in vitro fertilization (IVF) or working with a surrogate. By screening embryos for chromosomal abnormalities before transfer, PGT-A aims to increase the chances of a successful, healthy pregnancy. But is it right for everyone? In this comprehensive guide, we explain what PGT-A is, how it works, who should consider it, and what the latest research tells us about its effectiveness and limitations. What Is PGT-A? PGT-A stands for Preimplantation Genetic Testing for Aneuploidy, formerly known as PGS (Preimplantation Genetic Screening). It is a laboratory procedure performed on embryos before they are transferred into the uterus. The goal is to detect chromosomal aneuploidies—embryos with too few or too many chromosomes—that can lead to failed implantation, miscarriage, or genetic disorders like Down syndrome. PGT-A differs from: - PGT-M, which tests for specific inherited diseases (monogenic disorders), - PGT-SR, which screens for structural chromosomal rearrangements. Why Is PGT-A Performed? The main purposes of PGT-A include: - Selecting chromosomally normal embryos (euploid) for transfer - Reducing the risk of miscarriage - Improving implantation and live birth rates - Avoiding transferring embryos with conditions like trisomy 21 (Down syndrome) A study published in Fertility and Sterility (2019) found that PGT-A increased implantation rates in patients aged 35 and older by over 15% compared to non-screened embryos. Who Should Consider PGT-A? PGT-A Pass Rates by Age Group One of the strongest predictors of whether an embryo will be chromosomally normal is the age of the woman who produced the egg. The older the woman, the more likely her eggs will have chromosomal abnormalities. The chart below shows the approximate PGT-A (formerly PGS) pass rates by age group, based on large-scale data from a genetic testing laboratory: - Egg Donors (typically under 30): 64% - Under 35 years old: 57% - 35–37 years old: 49% - 38–40 years old: 37% - 41–42 years old: 24% - Over 42 years old: 16% This data illustrates why PGT-A is often recommended for women over 35 and why donor eggs—especially from younger donors—tend to produce higher-quality embryos with better chances of success. While PGT-A can be considered by any IVF patient, it is especially recommended for: - Women over 35 years old - Couples with recurrent pregnancy loss - Patients with repeated failed IVF cycles - Intended parents using donor eggs and wishing to minimize risk - Parents undergoing surrogacy, especially with only one or two embryos to transfer - Families who wish to select the sex of their baby for family balancing or personal reasons PGT-A may also be considered in cases where intended parents want to electively transfer a single embryo (eSET) to reduce the risks associated with multiple pregnancies. In a 2021 meta-analysis published in Human Reproduction Update, researchers found that live birth rates were significantly higher in the PGT-A group among women aged 35 and older, but the difference was not significant in women under 35. The PGT-A Process: Step-by-Step - Egg retrieval and fertilization via IVF - Embryo development to blastocyst stage (Day 5-7) - Trophectoderm biopsy: 5–10 cells are carefully removed from the outer layer of the embryo (not the part that becomes the fetus) - Embryo vitrification (freezing) - Genetic analysis using NGS (Next-Generation Sequencing) - Embryo transfer based on results, selecting a euploid embryo The results typically take 7–10 days, and embryos remain frozen until transfer. Understanding PGT-A Results: What Your Report Means When you receive your PGT-A report, the results typically categorize each embryo into one of several classifications: - Euploid: This embryo has the correct number of chromosomes (46 total). These embryos are considered the most likely to result in a successful pregnancy and are usually prioritized for transfer. - Aneuploid: This embryo has an abnormal number of chromosomes (e.g., 45 or 47), indicating a full chromosomal gain or loss. These are usually not recommended for transfer due to a high risk of miscarriage or birth defects. - Mosaic: This embryo contains both normal (euploid) and abnormal (aneuploid) cells. The degree of mosaicism may be classified as low-level (20–40%) or high-level (40–80%). Some clinics may consider transferring low-level mosaic embryos under close monitoring, though success rates may be lower and risks higher. - Segmental Aneuploidy: This means a portion of a chromosome (rather than an entire chromosome) is duplicated or deleted. The significance depends on the size and location of the affected segment. Interpretation is more complex and often requires genetic counseling. - No Result / Inconclusive: Sometimes, the biopsy sample is insufficient or fails during testing. In such cases, clinics may offer to re-biopsy or consider the embryo as untested. Understanding your PGT-A report requires guidance from a reproductive endocrinologist or genetic counselor who can assess the clinical implications and help you decide which embryos are most suitable for transfer. How Accurate Is PGT-A? PGT-A is generally over 95% accurate in detecting full chromosomal aneuploidies, according to the American Society for Reproductive Medicine (ASRM). However, it's not infallible. Limitations include: - False positives/negatives: For example, we once worked with a pair of intended parents who transferred a PGT-A normal embryo into a surrogate. The pregnancy began normally, but during the second-trimester anatomy scan, the fetus was found to have a severe congenital heart defect. Amniocentesis later confirmed Trisomy 18 (Edwards syndrome). This case highlights that PGT-A, while highly accurate, is not 100% foolproof. - Mosaicism: when the embryo contains both normal and abnormal cells. Some mosaic embryos may still result in healthy live births - Potential discarding of viable embryos due to uncertain results Risks and Limitations - Embryo damage risk during biopsy (minimal with modern techniques) - Cost, as PGT-A is not always covered by insurance - Emotional impact: discarding embryos due to abnormal results - PGT-A does not test for all diseases—it only looks at chromosome numbers, not gene-level mutations (unlike PGT-M) Cost of PGT-A in the U.S. PGT-A is an out-of-pocket expense for many families. Here’s what to expect: - Testing for up to 6 embryos: $3,000 – $6,000 - Each additional embryo: ~$250–$400 - Some fertility clinics bundle PGT-A into their IVF packages Surrogacy journeys that include PGT-A may incur higher upfront costs but potentially reduce the cost of failed transfers or miscarriage later. Ethical and Emotional Considerations PGT-A raises questions that intended parents should consider carefully: - What happens to embryos labeled as abnormal or mosaic? - Do we transfer lower-quality embryos if no euploid ones are available? - Are we comfortable with the idea of embryo selection? Some religious or ethical frameworks may discourage or prohibit embryo testing. However, for many, PGT-A provides peace of mind. PGT-A in Surrogacy and Egg Donation While egg donors do not undergo PGT-A themselves, embryos created from donor eggs are often tested via PGT-A. This is especially common when: - Intended parents are transferring embryos to a surrogate - There are multiple embryos, and selecting the “best” one increases chances of success - Parents want to reduce uncertainty, especially when using a high-cost donor cycle In short: PGT-A enhances the efficiency of egg donation and surrogacy, even if it doesn’t involve the donor directly. Conclusion: Is PGT-A Right for You? PGT-A is a powerful tool in the IVF and surrogacy journey—but it’s not a guarantee, and it’s not for everyone. For older patients, those with failed IVF cycles, or families using donor eggs or a surrogate, PGT-A may improve outcomes and reduce risk. Always speak with a fertility specialist and genetic counselor before deciding whether PGT-A is a good fit for your family-building plan. 📚 References - Forman EJ et al. Fertility and Sterility, 2019. - Greco E et al. New England Journal of Medicine, 2015. - Mastenbroek S et al. Human Reproduction Update, 2021. - ASRM Practice Committee Guidelines, 2023. - Capalbo A et al. Reproductive Biomedicine Online, 2020. 💬 Have Questions About PGT-A? We’re Here to Help. At Ivy Surrogacy, we understand how complex and emotional the IVF journey can be—especially when it comes to making decisions about genetic testing. If you’re wondering whether PGT-A is right for you, or how it fits into your surrogacy or donor egg plan, our experienced team is happy to guide you. Reach out today for a personalized consultation, and let’s talk about the best path forward for your family. 👉 Contact Us or Start Your Application Read the full article

#EmbryoScreening #GeneticTestinginIVF #IVFwithPGT-A #PGT-A #PreimplantationGeneticTesting

Embryo Enhancement Strategies: Preimplantation Genetic Diagnosis

What is PGD?

PGD, or preimplantation genetic diagnosis, is a procedure performed on embryos prior to implantation in the womb. During in vitro fertilization (IVF), embryos are created through fertilization in a laboratory dish and are allowed to develop for a few days. At this early stage, one or two cells are gently removed from the embryo and tested for genetic abnormalities and conditions. Only healthy embryos, as determined by PGD, are selected for implantation. The History of PGD

The first baby born through PGD was in 1990 after testing for cystic fibrosis. In the years since, the technique has improved and can now test for hundreds of genetic disorders. Initially, PGD was used for serious hereditary conditions like cystic fibrosis, Tay-Sachs disease, sickle cell anemia, and muscular dystrophy. Today, it is also applied to detect chromosomal abnormalities like Down syndrome and gender selection for X-linked disorders. PGD has helped many couples avoid passing on serious genetic diseases to their children. The PGD Process

The general steps involved in PGD are:

1) IVF treatment is performed as normal to collect multiple eggs from the female patient. 2) Eggs are fertilized with sperm in the lab to create embryos. 3) Typically on day 3 of development, when the embryo contains 6-10 cells, one or two cells are gently removed for biopsy without harming embryonic development. 4) The biopsied cells are analyzed using techniques like fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) to detect abnormalities. 5) Only healthy embryos, as confirmed by PGD results, are selected and implanted back into the woman's womb. Diseases Screened by PGD

Some of the more common genetic disorders for which PGD is often used include: - Cystic fibrosis: A lung disease caused by mutations in the CFTR gene. PGD can detect affected embryos. - Huntington's disease: A neurodegenerative condition caused by CAG repeat expansions. PGD finds embryos free of expansions. - Fragile X syndrome: The most common form of inherited intellectual disability caused by mutations in the FMR1 gene. Embryos can be tested. - Myotonic dystrophy: A muscular dystrophy caused by CTG repeat expansions that PGD can identify in embryos. - Beta thalassemia: An anemia caused by mutations in the HBB gene. PGD selects unaffected embryos. - Sickle cell anemia: Another anemia caused by a mutation in the HBB gene. PGD accurately diagnoses embryos. How Accurate is PGD?

As the techniques used for PGD continue to improve, the tests have become highly accurate. FISH analysis has an accuracy rate of about 95-99% while PCR-based methods detect abnormalities with over 99% accuracy. However, there is still a small chance of diagnostic errors. PGD is not currently able to test for all known genetic disorders and conditions either. While it has helped many couples, PGD is not perfect and misdiagnosis is still possible in a small number of cases. Continued clinical testing and experience will help further enhance the accuracy and reliability of PGD. Overall, when performed by experienced centers, PGD provides an effective method for screening embryos. Limitations and Ethical Considerations

While PGD addresses the desire to have healthy, genetically related children, it is not without limitations and ethical concerns. Aside from occasional misdiagnosis risks, PGD is not accessible or affordable for all couples and families affected by genetic disorders. The procedure is also limited to testing only those disorders with a known genetic cause and diagnostic test. There are ongoing debates around the widening scope of what conditions PGD is used for, including gender selection for social reasons alone. Some argue this could eventually lead to selecting embryos for traits like intelligence or athletic ability. Most experts agree PGD should only be offered for preventing medical disease or conditions. Overall, PGD is an advancing technology that provides benefit but also responsibility in its application. In conclusion, through the advances of preimplantation genetic diagnosis, modern science now offers new hope for couples at high risk of passing on life-altering genetic disorders. When performed carefully by trained professionals, PGD has proven an effective tool for pre-implantation diagnosis of embryos. Continued progress is still needed to further increase accuracy, expand testing options, and ensure judicious application in line with ethical standards. Looking ahead, PGD promises more couples the ability to have healthy children free of devastating genetic diseases.

#GeneticInsightPGD #EmbryoScreening #PreimplantationGenetics